Last reviewed · How we verify
Gadavist
At a glance
| Generic name | Gadavist |
|---|---|
| Also known as | Gadobutrol, gadobutrol |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Magnetic resonance imaging
Common side effects
- Headache
- Nausea
- Dizziness
- Dysgeusia
- Feeling Hot
- Injection site reactions
- Vomiting
- Rash
- Erythema
- Paresthesia
- Pruritus
- Dyspnea
Serious adverse events
- Nephrogenic systemic fibrosis
- Cardiac arrest
- Acute respiratory distress syndrome
- Anaphylactic shock
- Respiratory arrest
- Circulatory collapse
- Pulmonary edema
- Acute pancreatitis
- Laryngeal edema
- Bronchospasm
Key clinical trials
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Dotarem vs Gadobutrol Contrast for Breast MRI (PHASE4)
- A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients (PHASE2, PHASE3)
- Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- Novel Imaging Technique to Assess Gynecologic Cancer (PHASE1)
- Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease (NA)
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions (PHASE3)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadavist CI brief — competitive landscape report
- Gadavist updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI